Cytek Biosciences (CTKB) Receivables - Other (2020 - 2026)

Cytek Biosciences' Receivables - Other history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Receivables - Other rose 29.5% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 29.5% YoY) and the FY2025 annual result came in at $2.5 million, up 46.33% from the prior year.
• Receivables - Other was $2.2 million for Q1 2026 at Cytek Biosciences, down from $2.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $18.0 million in Q1 2022 and bottomed at $1.7 million in Q4 2024.
• A 5-year average of $3.1 million and a median of $2.2 million in 2025 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 47.85% — and 2023, when it sank 89.41%.
• Cytek Biosciences' Receivables - Other stood at $2.2 million in 2022, then advanced by 18.4% to $2.6 million in 2023, then tumbled by 33.42% to $1.7 million in 2024, then soared by 46.33% to $2.5 million in 2025, then slipped by 11.5% to $2.2 million in 2026.
• Business Quant data shows CTKB's Receivables - Other at $2.2 million in Q1 2026, $2.5 million in Q4 2025, and $2.2 million in Q3 2025.